Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Flowserve Corporation Common Stock (FLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Flowserve Corporation Common Stock — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Flowserve Corporation Common Stock trades at $69.78 (market cap $9.08B). The key difference: Flowserve Corporation Common Stock is far larger — about 3.2× Dyne Therapeutics Inc. Common Stock's market cap, and Flowserve Corporation Common Stock pays a 1.23% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Flowserve Corporation Common Stock for 6 Days on average.
| DYN | FLS | |
|---|---|---|
Market Cap | $2.86B | $9.08B |
Volume | 3,341,579 | 1,742,251 |
Sector | Health | Industrials |
52-Week High | $26.78 | $92.04 |
52-Week Low | $14.60 | $50.41 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.18B | $10.67B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
FLS trades at $71.47, up 1.16% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q3 2026 results pending. Revenue for 2025 was $4.73 billion, with a net income margin of 8.01%. Recent news includes a new CFO appointment and a quarterly dividend declaration.
The outlook is mixed: strong fundamentals and a consensus price target of $90.75 suggest upside, but technical weakness and a high P/E of 24.9 pose risks. Key opportunities include strategic acquisitions and nuclear market exposure, while headwinds include weak organic sales and rising debt levels noted by analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Flowserve Corporation Common Stock
Flowserve Corporation is a Texas-based manufacturer of engineered flow-control equipment, producing industrial pumps, mechanical seals, valves, and automation products through its Flowserve Pumps Division and Flow Control Division, serving the oil and gas, chemical, power, and water industries in more than 50 countries.
Read more on FLS →
